MedTrace Logo

Hormonal Replacement Therapy and Small Artery Function

NCT00564031 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2007-11-27

No results posted yet for this study

Summary

Endothelial dysfunction in resistance arteries in women after the menopause is important for the development of high blood pressure and cardiovascular disease

Conditions

Interventions

DRUG

Femanest

2mg/day

DRUG

gestapuran

5mg/day

DRUG

placebo

daily

DRUG

Femanest plus Gestapuran

combined daily

Sponsors & Collaborators

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Karolina Kublickiene, MD PhD · Karolinska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-01-31
Completion
2004-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00564031 on ClinicalTrials.gov